FSA
VRTX icon

Fort Sheridan Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Fort Sheridan Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860K Buy
1,731
+57
+3% +$25.3K 0.09% 133
2026
Q1 		$748K Sell
1,674
-328
-16% -$153K 0.09% 141
2025
Q4 		$908K Hold
2,002
– – 0.12% 115
2025
Q3 		$784K Sell
2,002
-74
-4% -$30.9K 0.1% 123
2025
Q2 		$924K Sell
2,076
-352
-14% -$162K 0.13% 112
2025
Q1 		$1.18M Buy
2,428
+4
+0.2% +$1.86K 0.18% 81
2024
Q4 		$976K Buy
2,424
+386
+19% +$179K 0.14% 105
2024
Q3 		$948K Buy
2,038
+11
+0.5% +$5.28K 0.14% 101
2024
Q2 		$950K Buy
2,027
+352
+21% +$153K 0.15% 93
2024
Q1 		$700K Buy
1,675
+107
+7% +$45.2K 0.13% 105
2023
Q4 		$638K Sell
1,568
-300
-16% -$111K 0.13% 107
2023
Q3 		$650K Hold
1,868
– – 0.15% 102
2023
Q2 		$657K Hold
1,868
– – 0.15% 98
2023
Q1 		$589K Buy
1,868
+376
+25% +$113K 0.15% 101
2022
Q4 		$431K Hold
1,492
– – 0.14% 113
2022
Q3 		$432K Hold
1,492
– – 0.15% 110
2022
Q2 		$421K Buy
1,492
+352
+31% +$94.2K 0.14% 110
2022
Q1 		$298K Sell
1,140
-161
-12% -$38.2K 0.09% 142
2021
Q4 		$286K Buy
+1,301
New +$253K 0.08% 158
2021
Q2 		– Sell
-1,151
Closed -$247K – 192
2021
Q1 		$247K Sell
1,151
-689
-37% -$151K 0.1% 132
2020
Q4 		$435K Buy
+1,840
New +$422K 0.21% 66
2020
Q3 		– Sell
-700
Closed -$203K – 118
2020
Q2 		$203K Buy
+700
New +$190K 0.12% 96

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fort Sheridan Advisors's VRTX Position: Q2 2026 in Review

Fort Sheridan Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q2 2026, buying an estimated $25.3K and bringing the position to 1,731 shares worth $860K. The position accounts for 0.09% of the portfolio, ranked #133.

Fort Sheridan Advisors first reported a position in VRTX in Q2 2020 and has held it in 22 quarters since. The position peaked at $1.18M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fort Sheridan Advisors held 1,731 shares of Vertex Pharmaceuticals worth $860K as of Q2 2026.
  • Fort Sheridan Advisors bought 57 Vertex Pharmaceuticals shares in Q2 2026, an estimated $25.3K.
  • Vertex Pharmaceuticals made up 0.09% of Fort Sheridan Advisors's portfolio in Q2 2026, its #133 holding.
  • Fort Sheridan Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Fort Sheridan Advisors's Vertex Pharmaceuticals position peaked at $1.18M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fort Sheridan Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.